UCB, Inc. (UCBJF.PK) Launches Neupro® in the U.S. to Treat Parkinson's Disease and Restless Legs Syndrome
7/16/2012 9:43:15 AM
BRUSSELS & ATLANTA--(BUSINESS WIRE)--UCB announced today that Neupro® (Rotigotine Transdermal System) is now available in U.S. pharmacies. Neupro® was approved by the U.S. Food and Drug Administration in April to treat the signs and symptoms of early and advanced stage idiopathic Parkinson’s disease and moderate-to-severe primary Restless Legs Syndrome.
comments powered by